secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0000950170-24-010093
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Samuel J. Reich appointed CEO of SAB Biotherapeutics; remains Executive Chairman
--------------------------------------------------------------------------------

- Reich expands role from Executive Chairman to CEO effective February 2, 2024.
- Co-founder Eddie J. Sullivan continues as President and board member, leading operations and R&D.
- Reich co-founded Biscayne Neurotherapeutics (sold to Supernus) and Acuity Pharmaceuticals.
- Company advancing lead candidate SAB-142 for delaying type 1 diabetes progression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/0000950170-24-010093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/sabs-20240130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-010093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer